Silverman Barbara G, Lipshitz Irena, Keinan-Boker Lital
, , and , Israel Ministry of Health, Ramat Gan; , Tel Aviv University, Tel Aviv; and , University of Haifa, Haifa, Israel.
J Glob Oncol. 2016 Jun 29;3(2):135-142. doi: 10.1200/JGO.2016.003699. eCollection 2017 Apr.
Improvements in early detection and treatment have resulted in improved long-term survival from breast cancer, which increases the likelihood of the occurrence of second primary cancers. We calculated the risk of second primary cancers among Israeli women receiving a first primary breast cancer diagnosis.
By using data from the Israel National Cancer Registry, we identified 46,090 women with invasive breast cancer diagnosed between 1990 and 2006 and non-breast primary cancers diagnosed subsequent to breast cancer diagnosis. We used life table analysis to calculate the risk of a second primary cancer and calculated standardized incidence ratios (SIRs) by using age-specific cancer risk in the general population of Israeli women as the standard and stratifying by diagnosis period (1992 to 1996, 1997 to 2001, 2002 to 2006) and age at diagnosis (< 50 and ≥ 50 years).
The probability of a second malignancy was 3.6% within 5 years, 8.2% within 10 years, and 13.9% within 15 years. The SIR for any second non-breast primary cancer was 1.26 (95% CI, 1.23 to 1.30). Significantly increased risks of colorectal, uterine, lung, ovarian, and thyroid cancer and leukemia were observed for the full follow-up period, which persisted after excluding the first 6 months after index diagnosis, although increased leukemia and colorectal cancer risks were no longer statistically significant. Women younger than age 50 years at initial diagnosis had a greater excess risk than women age 50 years and older (SIR, 1.77 [95% CI, 1.63 to 1.91] and 1.20 [95% CI, 1.15 to 1.24], respectively).
The findings likely reflect a combination of personal risk factors (genetics, hormonal therapy, environmental exposures) as well as the effects of the initial cancer treatment and are unlikely to be explained by enhanced surveillance alone.
早期检测和治疗的改善已使乳腺癌患者的长期生存率提高,这增加了第二原发性癌症发生的可能性。我们计算了首次诊断为原发性乳腺癌的以色列女性中发生第二原发性癌症的风险。
通过使用以色列国家癌症登记处的数据,我们确定了1990年至2006年间诊断为浸润性乳腺癌且在乳腺癌诊断后诊断为非乳腺原发性癌症的46,090名女性。我们使用生命表分析来计算第二原发性癌症的风险,并以以色列女性总体人群中特定年龄的癌症风险为标准,按诊断期(1992年至1996年、1997年至2001年、2002年至2006年)和诊断时年龄(<50岁和≥50岁)进行分层,计算标准化发病比(SIR)。
5年内发生第二种恶性肿瘤的概率为3.6%,10年内为8.2%,15年内为13.9%。任何第二种非乳腺原发性癌症的SIR为1.26(95%CI,1.23至1.30)。在整个随访期间,观察到结直肠癌、子宫癌、肺癌、卵巢癌、甲状腺癌和白血病的风险显著增加,在排除索引诊断后的前6个月后这些风险仍然存在,尽管白血病和结直肠癌风险增加不再具有统计学意义。初次诊断时年龄小于50岁的女性比50岁及以上的女性有更大的超额风险(SIR分别为1.77[95%CI,1.63至1.91]和1.20[95%CI,1.15至1.24])。
这些发现可能反映了个人风险因素(遗传、激素治疗、环境暴露)的综合作用以及初始癌症治疗的影响,不太可能仅通过加强监测来解释。